This study demonstrated association of 12 spatially informed biomarkers to clinical outcome (PFS and/or OS) in NSCLC. Authors emphasized clinical potential of high CD56+ level in CD45+ compartment as the prognostic factor for PD-1 checkpoint blockade treatment. This evidence concerns the gene NCAM1 and non-small cell lung carcinoma.